Truist reiterates Buy on Option Care Health stock amid sale talks

Truist Securities has maintained its positive outlook on Option Care Health (OPCH) stock, reiterating a Buy rating with a price target of $30.00 following reports of advanced sale talks. The Financial Times revealed the company is in negotiations to sell to McKesson and Clayton Dubilier & Rice for a valuation surpassing $5 billion, with a potential announcement by October 6. As of October 5, Option Care Health's enterprise value was recorded at $4.55 billion.

Truist emphasizes the company's strategic positioning due to industry growth factors, such as an aging population and the shift towards lower-cost, patient-preferred care settings. Additionally, Truist highlights the company's strong payer relationships, in-network status with top providers, and coverage of 96% of insured lives as advantageous factors.

The firm remains bullish on Option Care Health's portfolio, citing its diverse assets, including a sizable Advanced Provider Services (APS) footprint, a growing advanced practitioner model, and robust free cash flow generation.

Recent analyst sentiment supports Truist's optimism, with 5 analysts revising their earnings estimates upward for the upcoming period. The company's second-quarter earnings exceeded expectations, with adjusted earnings per share of $0.45 surpassing the consensus estimate of $0.43. Revenue for the quarter also surpassed projections at $1.44 billion, compared to the anticipated $1.42 billion.

Management cited improving cash flow and stronger adjusted EBITDA, along with a narrowed full-year profit guidance, which reassured investors despite ongoing challenges in the chronic inflammatory disease business.

Other analysts maintain mixed views on the stock. UBS maintained its Buy rating with a price target of $39.00, praising the company's consistent messaging and execution focus. Conversely, Deutsche Bank downgraded the stock to Hold, reducing its price target from $26.00 to $24.00, citing growth concerns. Deutsche Bank's analyst, Pito Chickering, acknowledged an EBITDA beat but expressed disappointment in the company's adjusted guidance reduction.